Esperion Therapeutics (ESPR) Short term Debt (2014 - 2018)

Esperion Therapeutics' Short term Debt history runs 5 years deep, the most recent figure standing at $152000.0 for Q2 2018.

• Quarterly Short term Debt fell 91.38% year-over-year to $152000.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $152000.0 (down 91.38% YoY) and the FY2017 annual result came in at $1.0 million, down 38.85% from the prior year.
• Short term Debt was $152000.0 for Q2 2018 at Esperion Therapeutics, down from $603000.0 in the prior quarter.
• Across five years, Short term Debt topped out at $1.8 million in Q2 2017 and bottomed at $152000.0 in Q2 2018.
• A 5-year average of $1.2 million and a median of $1.5 million in 2015 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2015 — Short term Debt soared 523.72% — and 2018, when it tumbled 91.38%.
• Esperion Therapeutics' Short term Debt stood at $638000.0 in 2014, then surged by 151.41% to $1.6 million in 2015, then advanced by 6.55% to $1.7 million in 2016, then plunged by 38.85% to $1.0 million in 2017, then plunged by 85.45% to $152000.0 in 2018.
• Business Quant data shows ESPR's Short term Debt at $152000.0 in Q2 2018, $603000.0 in Q1 2018, and $1.0 million in Q4 2017.